Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to acquire Nightstar Therapeutics, a UK-based clinical-stage gene therapy company, in a deal valued at $800 million. The acquisition underscores Biogen’s commitment to expanding its pipeline, particularly in the ophthalmology space, where it aims to address rare and […]